Oral cancer stem cells: A comprehensive review of key drivers of treatment resistance and tumor recurrence.

IF 4.2 3区 医学 Q1 PHARMACOLOGY & PHARMACY
European journal of pharmacology Pub Date : 2025-02-15 Epub Date: 2025-01-02 DOI:10.1016/j.ejphar.2024.177222
Nagarathna P J, Santosh R Patil, Vishnu Priya Veeraraghavan, Shikhar Daniel, Kaladhar Reddy Aileni, Mohmed Isaqali Karobari
{"title":"Oral cancer stem cells: A comprehensive review of key drivers of treatment resistance and tumor recurrence.","authors":"Nagarathna P J, Santosh R Patil, Vishnu Priya Veeraraghavan, Shikhar Daniel, Kaladhar Reddy Aileni, Mohmed Isaqali Karobari","doi":"10.1016/j.ejphar.2024.177222","DOIUrl":null,"url":null,"abstract":"<p><p>Oral squamous cell carcinoma (OSCC) remains a major cause of morbidity and mortality worldwide with high recurrence rates and resistance to conventional therapies. Recent studies have highlighted the pivotal role of oral cancer stem cells (OCSCs) in driving treatment resistance and tumor recurrence. OCSCs possess unique properties, including self-renewal, differentiation potential, and resistance to chemotherapy and radiotherapy, which contribute to their ability to survive treatment and initiate tumor relapse. Several signaling pathways, such as Wnt/β-catenin, Hedgehog, Notch, and PI3K/Akt/mTOR, have been implicated in maintaining OCSC properties, promoting survival, and conferring resistance. Additionally, mechanisms such as drug efflux, enhanced DNA repair, epithelial-mesenchymal transition (EMT), and resistance to apoptosis further contribute to resilience. Targeting these pathways offers promising therapeutic strategies for eliminating OCSCs and improving treatment outcomes. Approaches such as immunotherapy, nanotechnology-based drug delivery, and targeting of the tumor microenvironment are emerging as potential solutions to overcome OCSC-mediated resistance. However, further research is needed to fully understand the molecular mechanisms governing OCSCs and develop effective therapies to prevent tumor recurrence. This review discusses the role of OCSCs in treatment resistance and recurrence and highlights the current and future directions for targeting these cells in OSCC.</p>","PeriodicalId":12004,"journal":{"name":"European journal of pharmacology","volume":" ","pages":"177222"},"PeriodicalIF":4.2000,"publicationDate":"2025-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European journal of pharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.ejphar.2024.177222","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/2 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Oral squamous cell carcinoma (OSCC) remains a major cause of morbidity and mortality worldwide with high recurrence rates and resistance to conventional therapies. Recent studies have highlighted the pivotal role of oral cancer stem cells (OCSCs) in driving treatment resistance and tumor recurrence. OCSCs possess unique properties, including self-renewal, differentiation potential, and resistance to chemotherapy and radiotherapy, which contribute to their ability to survive treatment and initiate tumor relapse. Several signaling pathways, such as Wnt/β-catenin, Hedgehog, Notch, and PI3K/Akt/mTOR, have been implicated in maintaining OCSC properties, promoting survival, and conferring resistance. Additionally, mechanisms such as drug efflux, enhanced DNA repair, epithelial-mesenchymal transition (EMT), and resistance to apoptosis further contribute to resilience. Targeting these pathways offers promising therapeutic strategies for eliminating OCSCs and improving treatment outcomes. Approaches such as immunotherapy, nanotechnology-based drug delivery, and targeting of the tumor microenvironment are emerging as potential solutions to overcome OCSC-mediated resistance. However, further research is needed to fully understand the molecular mechanisms governing OCSCs and develop effective therapies to prevent tumor recurrence. This review discusses the role of OCSCs in treatment resistance and recurrence and highlights the current and future directions for targeting these cells in OSCC.

口腔癌干细胞:治疗耐药和肿瘤复发的关键驱动因素的综合综述。
口腔鳞状细胞癌(OSCC)仍然是世界范围内发病率和死亡率的主要原因,具有高复发率和对常规治疗的耐药性。最近的研究强调了口腔癌干细胞(OCSCs)在驱动治疗耐药和肿瘤复发中的关键作用。OCSCs具有独特的特性,包括自我更新、分化潜能和对化疗和放疗的耐药性,这有助于它们在治疗中存活并引发肿瘤复发。几种信号通路,如Wnt/β-catenin、Hedgehog、Notch和PI3K/Akt/mTOR,都与维持OCSC特性、促进生存和赋予抗性有关。此外,药物外排、DNA修复增强、上皮-间质转化(epithelial- mesenchal transition, EMT)和细胞凋亡抵抗等机制也有助于恢复。靶向这些通路为消除OCSCs和改善治疗结果提供了有希望的治疗策略。免疫疗法、基于纳米技术的药物传递和靶向肿瘤微环境等方法正在成为克服ocsc介导的耐药性的潜在解决方案。然而,需要进一步的研究来充分了解OCSCs的分子机制,并开发有效的治疗方法来预防肿瘤复发。本文讨论了OCSCs在治疗耐药和复发中的作用,并强调了目前和未来在OSCC中靶向这些细胞的方向。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
9.00
自引率
0.00%
发文量
572
审稿时长
34 days
期刊介绍: The European Journal of Pharmacology publishes research papers covering all aspects of experimental pharmacology with focus on the mechanism of action of structurally identified compounds affecting biological systems. The scope includes: Behavioural pharmacology Neuropharmacology and analgesia Cardiovascular pharmacology Pulmonary, gastrointestinal and urogenital pharmacology Endocrine pharmacology Immunopharmacology and inflammation Molecular and cellular pharmacology Regenerative pharmacology Biologicals and biotherapeutics Translational pharmacology Nutriceutical pharmacology.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信